You just read:

Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Jul 31, 2017, 03:00 ET